Apr 28, 2022
Real-World Data to Support HTAs in Europe
In this new episode titled "Real-World Data to Support HTAs in Europe", we will examine the various uses of Real-World Data (RWD) and how it is valued in Health Technology Assessments in multiple European nations. Learn more about using RWD as support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Meet our guests:
Catia Proenca – Director, Clinical Real-World Evidence, Alira Health
Catia designs and manages Real-World Evidence strategies maintaining a Market Access perspective by ensuring key stakeholder needs (e.g., HTA, payers) are met, thus, maximizing access to innovation, and ultimately improving patient outcomes. With 13+ years of experience in industry and academia, Catia’s previous roles include positions at Wellmera, Novartis Global, and the Novartis Institute for Biomedical Research. Catia holds a PhD in Neuroscience from the Weill Cornell Medical College, New York, and the University of Lisbon.
Carsten Schwenke – HTA Expert
Carsten Schwenke is a licensed biostatistician and health economist, with a PhD in public health, that has 25 years of experience in the pharmaceutical sector, focusing on clinical development and market access. He has been self-employed for the past 15 years, with a primary focus on the German HTA process.
Meet our host:
Kenny Carberry – Director, Clinical Development, Alira Health
Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers various indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle, from generating a comprehensive strategy to executing a successful trial.